SCHEMBL30656273

SCHEMBL30656273

N#Cc1c(N)nc(-c2ccccc2)c(C#N)c1-c1cccc(-c2ccccc2Cl)c1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 14/20 0.60
ADORA1 P30542 14/20 0.60
ADORA2B P29275 4/20 0.54
KDM4E B2RXH2 4/20 0.51
ALDH1A1 P00352 3/20 0.51
HSD17B10 Q99714 1/20 0.50
HPGD P15428 3/20 0.49
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
MAPT P10636 2/20 0.49
HIF1A Q16665 2/20 0.49
GALR3 O60755 1/20 0.49
LMNA P02545 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
POLB P06746 1/20 0.46
STAT6 P42226 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26632966 1.00 ADORA2A (0.60) ADORA2AADORA1ADORA2BKDM4EALDH1A1
SCHEMBL26632980 0.86 ADORA2A (0.51) ADORA2AADORA1ADORA2BKDM4EALDH1A1
SCHEMBL31215445 0.86 ADORA2A (0.51) ADORA2AADORA1ADORA2BKDM4EALDH1A1
SCHEMBL30656290 0.85 ADORA1 (0.54) ADORA2AADORA1ADORA2BKDM4EALDH1A1
SCHEMBL26632983 0.85 ADORA1 (0.54) ADORA2AADORA1ADORA2BKDM4EALDH1A1
SCHEMBL30656135 0.85 ADORA1 (0.71) ADORA2AADORA1ADORA2BKDM4EHSD17B10
SCHEMBL26632952 0.85 ADORA1 (0.71) ADORA2AADORA1ADORA2BKDM4EHSD17B10
SCHEMBL26632974 0.84 ADORA1 (0.59) ADORA2AADORA1ADORA2BKDM4EHSD17B10
SCHEMBL30656203 0.84 ADORA1 (0.59) ADORA2AADORA1ADORA2BKDM4EHSD17B10
SCHEMBL31215454 0.80 ADORA1 (0.61) ADORA2AADORA1ADORA2BKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4447962-B1 ADENOSINE 2A RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF CANCER UNIV GENEVE (CH) 2025-08-20 EP claimed
US-20250115592-A1 ADENOSINE 2A RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF CANCER UNIVERSITE DE GENEVE (CH) 2025-04-10 US claimed
CN-119136802-A Adenosine 2A receptor modulators for the treatment of cancer 瑞士日内瓦大学 2024-12-13 CN claimed
EP-4447962-A1 ADENOSINE 2A RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF CANCER UNIVERSITE DE GENEVE (CH) 2024-10-23 EP claimed
WO-2023213761-A1 ADENOSINE 2A RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF CANCER UNIVERSITE DE GENEVE (CH) 2023-11-09 WO claimed
EP-4447962-B1 ADENOSINE 2A RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF CANCER UNIV GENEVE (CH) 2025-08-20 EP disclosed
US-20250115592-A1 ADENOSINE 2A RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF CANCER UNIVERSITE DE GENEVE (CH) 2025-04-10 US disclosed
CN-119136802-A Adenosine 2A receptor modulators for the treatment of cancer 瑞士日内瓦大学 2024-12-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250115592-A1 ADENOSINE 2A RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF CANCER ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885ADORA2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.